NCT02535312
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin treatment 1 / 2 active_not_recruiting NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 terminated NCT02721732
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic treatment 2 active_not_recruiting NCT03087591
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery No drug interventions treatment 1 completed NCT04957615
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression treatment 2 recruiting NCT03366103
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors treatment 1 / 2 terminated NCT00576654
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT03217253
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction treatment 1 withdrawn NCT02503709
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT02070549
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction treatment 1 active_not_recruiting NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT02432963
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy treatment 1 active_not_recruiting NCT01738139
Ipilimumab and Imatinib Mesylate in Advanced Cancer treatment 1 completed NCT01822522
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus treatment 1 completed NCT02143401
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors treatment 1 active_not_recruiting NCT03291938
IACS-010759 in Advanced Cancers No drug interventions treatment 1 completed NCT04250597
Study of GNX102 in Patients With Advanced Solid Tumors No drug interventions treatment 1 terminated NCT02408861
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 recruiting NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma treatment 1 completed NCT03061188
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma treatment 1 completed NCT01787500
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT01012817
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer treatment 1 / 2 active_not_recruiting NCT02159989
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 completed NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer treatment 1 recruiting NCT06302621
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors treatment 1 recruiting NCT04914117
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours treatment 1 completed NCT06184035
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer treatment 1 / 2 recruiting NCT05086692
A Beta-only IL-2 ImmunoTherapY Study treatment 1 / 2 recruiting NCT05461664
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA No drug interventions Not Available Not Available unknown_status NCT05831579
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy No drug interventions treatment Not Available recruiting NCT06185556
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases No drug interventions treatment 2 / 3 recruiting NCT05464875
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors No drug interventions Not Available Not Available unknown_status NCT05759949
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors treatment 1 active_not_recruiting NCT04572451
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma treatment 1 recruiting